Endo, Orion to develop cancer drugs
This agreement allows the companies to develop a total of eight ‘discovery phase’ candidates by combining an equal number of programmes. It also permits both the companies to

This agreement allows the companies to develop a total of eight ‘discovery phase’ candidates by combining an equal number of programmes. It also permits both the companies to

The approval follows the approval of Rituxan for this indication by the European Commission in October 2010. The FDA approval was based on a Phase III study, which

The once daily tablet, Gralise is developed by Depomed and it is licensed to Abbott Products in US, Mexico and Canada. Depomed CEO Carl Pelzel said the approval

DigiFab is an antidote for digoxin toxicity. It works by binding to digoxin and preventing it from working in the body. Paladin Labs president and CEO Jonathan Ross

Mylan Pharma clams that Nisoldipne ER tablets are the generic version of Shiongi Pharma’s hypertension treatment, Sular. Sular (nisoldipine), Nisoldipine is in a group of drugs called calcium

The biotech company during July last year completed the spin-off of DNage as part of which the DNage was to get a bridge funding from the parent company

The study is being conducted in healthy male and female volunteers at a single site in the US under an investigational new drug (IND) application recently allowed by

The system is intended to reduce ingestion of counterfeit medications. The system will enable both prescription drug manufacturers and pharmacists to confirm and deliver appropriate and authentic medications

The Phase 1 cancer trial involved 6 patients with cancer metastatic to the liver or with recurrent liver cancer. According to Provectus Pharma, the primary objective of the

The company has also announced the launch of the treatment for the relief of moderate to moderately severe pain, Hydrocodone Bitartrate and Acetaminophen. Boca Pharmacal, a research and